DexCom, Inc. (DXCM) |
| 70.25 -0.73 (-1.03%) 01-13 16:00 |
| Open: | 70.89 |
| High: | 70.89 |
| Low: | 68.465 |
| Volume: | 7,620,016 |
| Market Cap: | 27,481(M) |
| PE Ratio: | 39.03 |
| Exchange: | NASDAQ Global Select |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 84.66 |
| Resistance 1: | 72.49 |
| Pivot price: | 68.09 |
| Support 1: | 67.24 |
| Support 2: | 64.00 |
| 52w High: | 93.25 |
| 52w Low: | 54.11 |
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
| EPS | 1.800 |
| Book Value | 6.990 |
| PEG Ratio | 0.00 |
| Gross Profit | 6.820 |
| Profit Margin (%) | 15.96 |
| Operating Margin (%) | 20.05 |
| Return on Assets (ttm) | 7.0 |
| Return on Equity (ttm) | 30.6 |
Mon, 12 Jan 2026
Barclays Downgrades DexCom (DXCM), Lowers Price Target to $71.00 - GuruFocus
Mon, 12 Jan 2026
(DXCM) DexCom Expects 2026 Total Revenue Range $5.16B - $5.25B, vs. FactSet Est of $5.23B - marketscreener.com
Mon, 12 Jan 2026
Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook - Business Wire
Fri, 09 Jan 2026
DexCom (DXCM) Price Target Raised by Bernstein | DXCM Stock News - GuruFocus
Fri, 09 Jan 2026
Why Dexcom (DXCM) Is Up 5.6% After Naming New CEO And Advancing AI Diabetes Platform - Sahm
Thu, 08 Jan 2026
DexCom (DXCM) Stock Falls as Analysts Adjust Price Targets | Jan 2026 - News and Statistics - IndexBox
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |